Dr. Hans Werner Griesser

Post Merger Integration Programs. Implementation of Solutions not possible before in complex and uncertain Environment. Portfolio Evaluation and Management. Crossfunctional Program Management. Transformation Management for People, Organisations and Teams to cope with novel Business Models.

- Revise and implement Group R&D strategy across sites - Strategic planning for exploitation of Company’s technologies - Qualify and turnaround R&D, System Integration, Operations - Revise operating systems & departments infrastructure for more efficiency - Stabilize and repair IDS ISYS legacy products - Define and implement iSYS system platform elements - Manage global partnerships converting ELISA/POC assays into automated products

• Benchmarked with MedTech • Strategic & operational portfolio management • Innovation screening & portfolio evaluation • Chang to lift Division Products onto performance level for industry leader for digital CADCAM prosthetics • Establish roles and responsibilities for business lead, project lead, functional leads • Implemented portfolio & project management framework across Business Units Implant, Regenerative, Prosthetics solutions • Product launches • OPEX/CAPEX planning & management

- Led initiative to merge 3 Business Areas (Centralized Diagnostics, Decentralized Diagnostics, Instrumentation) tp Roche Professional Diagnostics (RPD) - Implemented Portfolio Management and coordinated Portfolio Boards of 4 RPD Business Segments and Technology Board - Established regional country planning letters with reliable launch commitments and USPs - Cultural integration of RPD with other 5 fast growing organizations on CH campus introducing Complex Change, reporting to GM

- Implemented Program Management from R&D into Global Marketing - Aligned RDx System Roadmaps for platforms elements, derivatives and enabling technologies - Kept programs on target (budget responsibility between 10 and 80 mCHF per program) - Established information hub for laboratory workflows, market trends, innovations, competitor’s performance - Managed system release of cobas® 6000 platform in collaboration with HITACHI HHT Contributed to Roche Pharma/Roche Diagnostics “Fit to Win” initiative

- Led program to stabilize eroding business with Roche Diagnostics in Japan, major local reagents development companies and launch of 9000 series with HITACHI HHT - Managed system release of Modular Analytics SWA (2003) & Urisys 2400 (2003) - Increased top line by closing gap between product availability and country sales

- Merged 13 Roche/BM facilities to shape 4 new Centers of Excellence Transferred 360 products - Established & led post merger global Project Management Organization (PMO) - Negotiated &implemented joint “Development and Milestone Process” between Roche Diagnostics and HITACHI - Elaborated Roche Diagnostics (RD) “Divisional Project Management Framework - Managed programs for cobas® platforms (MODULAR Analytics, Modular Pre-Analytics, STA R, Modular E170 - Contributed to Microspot (Multiplex) program

- Designed & implemented scalable manufacturing facilities, equipment, products and processes at low cost of goods (50% vs. best competitor): (USD 9 m (invest for global facilities), USD 30 m (budget for global assay transfer) - Elecsys® Operations: Planning, realization, production output of appr. 0.5 mio kits/year, FDA, CE, TÜV - Managed 50 new Elecsys® assay transfers into manufacturing from 4 internal and 2 external sites including incl. clinical evaluations, CE & FDA approval and global supply chain

- Established and led the first organization in Roche Diagnostics to tramsfer IVD products from R&D into manufacturing - Increased annual launch rate from 4 upto 10 immunoassays per year

- Developed and launched 3 immunoassays at half turnaround time and half total project cost com pared to previous standard - Led change form functional silo driven mindset to crossfunctional collaboration of M&S, R&D, Operations for rapid commercialization

- Applied new technologies (genetical engineered proteins - Transferred R&D formulations for immunoassays test strips (Tutzing, D) into manufacturing (Mannheim (D)

Post doc fellow to explore malaria vaccines with Institute Pasteur (F). Purification of DNA and RNA, DNA cloned, PCR, hybrid proteins, protective antibodies.